{
    "clinical_study": {
        "@rank": "38713", 
        "brief_summary": {
            "textblock": "PRIMARY: To compare the virologic activity (quantitative RNA PCR, quantitative PBMC) of the\n      combination of nevirapine and zidovudine (AZT) versus AZT alone after 3 and 6 months of\n      treatment. To compare the effects of these two regimens on CD4 T-cell count and percentage.\n\n      SECONDARY: To compare and evaluate other markers of immunologic and virologic activity in\n      patients receiving nevirapine/AZT versus AZT alone. To compare the effects of the two\n      regimens on clinical signs and symptoms. To evaluate the safety and tolerance of the two\n      regimens."
        }, 
        "brief_title": "A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive combination nevirapine/AZT or AZT alone. Patients are evaluated for\n      virologic and immunologic activity at 3 and 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  PCP prophylaxis (trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine),\n             at the discretion of the investigator.\n\n          -  Antifungal prophylaxis with oral fluconazole or ketoconazole.\n\n          -  Antiviral prophylaxis for herpes simplex virus with <= 1000 mg/day oral acyclovir.\n\n          -  Dilantin for prevention and treatment of seizures.\n\n        Patients must have:\n\n          -  Asymptomatic HIV infection.\n\n          -  CD4 count 200-500 cells/mm3.\n\n          -  No prior AIDS.\n\n          -  No history of or active HIV-related thrush, vaginal candidiasis, zoster (shingles),\n             excessive weight loss, persistent fever, or diarrhea.\n\n          -  Tolerated 500-600 mg AZT daily for at least 4 months but no more than 12 months\n             immediately prior to study entry.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        NOTE:\n\n          -  Patients may not co-enroll in another protocol involving other investigational drugs\n             or biologics.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Malignancy other than limited cutaneous basal cell carcinoma.\n\n          -  Psychiatric condition sufficient to impair study compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Systemic glucocorticoids and steroid hormones.\n\n          -  Dicumarol, warfarin, and other anticoagulant medications.\n\n          -  Cimetidine.\n\n          -  Tolbutamide.\n\n          -  Doxycycline.\n\n          -  Chloramphenicol.\n\n          -  Phenobarbital and other barbiturates.\n\n          -  Foscarnet.\n\n          -  Erythromycin.\n\n          -  Amoxicillin-clavulanate (Augmentin).\n\n          -  Ticarcillin clavulanate.\n\n          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).\n\n          -  Any investigational drugs other than study drugs.\n\n        Patients with the following prior condition are excluded:\n\n        History of clinically important disease other than HIV infection, that may put patient at\n        risk because of participation in this study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretroviral medications other than AZT.\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Immunosuppressive or cytotoxic drugs or other experimental drugs.\n\n          -  Systemic glucocorticoids and steroid hormones.\n\n          -  Dicumarol, warfarin, and other anticoagulant medications.\n\n          -  Cimetidine.\n\n          -  Tolbutamide.\n\n          -  Doxycycline.\n\n          -  Chloramphenicol.\n\n          -  Phenobarbital and other barbiturates.\n\n          -  Foscarnet.\n\n          -  Erythromycin.\n\n          -  Amoxicillin-clavulanate (augmentin).\n\n          -  Ticarcillin clavulanate.\n\n          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).\n\n        Required:\n\n          -  AZT at 500-600 mg/day for at least 4 months but no more than 12 months immediately\n             preceding study entry.\n\n        Chronic use of alcohol or drugs sufficient to impair study compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002323", 
            "org_study_id": "200B", 
            "secondary_id": "BIPI 1037"
        }, 
        "intervention": [
            {
                "intervention_name": "Nevirapine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Nevirapine"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "Nevirapine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "946021018"
                    }, 
                    "name": "Highland Gen Hosp / San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63108"
                    }, 
                    "name": "Washington Univ School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "775550882"
                    }, 
                    "name": "Univ TX Galveston Med Branch"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cells/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002323"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2002"
    }, 
    "geocoordinates": {
        "Highland Gen Hosp / San Francisco Gen Hosp": "37.804 -122.271", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Northwestern Univ Med School": "41.878 -87.63", 
        "Univ TX Galveston Med Branch": "29.301 -94.798", 
        "Washington Univ School of Medicine": "38.627 -90.199"
    }
}